Loading clinical trials...
Loading clinical trials...
Phase I Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelofibrosis and Chronic Myelomonocytic Leukemia
Conditions
Interventions
Tagraxofusp
Locations
2
United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
University of Virginia
Charlottesville, Virginia, United States
Start Date
July 13, 2022
Primary Completion Date
July 1, 2026
Completion Date
October 1, 2026
Last Updated
May 28, 2025
NCT05564390
NCT03050268
NCT07320235
NCT06782542
NCT06439199
NCT07357727
Lead Sponsor
Karen Ballen, MD
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions